Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib plus BR in newly diagnosed MCL
NCT04849715Phase 3Withdrawn
- Sponsor
- Incyte
- Start
- Mar 2022
- Primary completion
- Aug 2030
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of parsaclisib in mantle cell lymphoma (MCL), sponsored by Incyte. Planned start Mar 2022; status: withdrawn.
02
Drugs
parsaclisib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04849715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849715.